CAR T cell therapy is showing promise as a treatment for gMG, potentially offering extended disease-free survival. While initial data are encouraging, safety concerns, especially neurotoxicity, remain significant. Ongoing studies are crucial to confirm the efficacy and safety of this innovative approach, aiming to revolutionize gMG treatment...

Efgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab.

Early conventional immunosuppressive drugs were effective, but a series of adverse events brought great physical and psychological burdens to patients, especially those who have been using them for a long-term period. In recent years, it is not only myasthenia gravis but also many neuroimmune diseases that have gone beyond the conventional...

The future of loco-regional anesthesia in robotic thoracic surgery is promising, with advancements in technology and precision medicine expected to enhance patient outcomes. As minimally invasive surgical approaches continue to gain popularity, there is a growing need for equally minimally invasive anesthetic techniques that provide effective...

While the exact pathogenesis of MG, LP, and thymoma co‐occurrence remains elusive, it suggests the possibility of a shared autoimmune mechanism. Various theories have been suggested to explain the association between thymoma and autoimmune disorders or paraneoplastic syndromes due to T lymphocyte dysfunction, genetic predisposition, and...